Literature DB >> 32020377

Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.

Jipei Liao1, Zejia Yang1, Brandon Carter-Cooper1, Elizabeth T Chang1, Eun Yong Choi1, Bhaskar Kallakury2, Xuefeng Liu2, Rena G Lapidus1, Kevin J Cullen1, Hancai Dan3,4.   

Abstract

We explored the role of the transcription factor, NF-κB, and its upstream kinase IKKβ in regulation of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma (HNSCC). We showed that cisplatin-resistant HNSCC cells have a stronger ability to migrate and invade, as well as display higher IKKβ/NF-κB activity compared to their parental partners. Importantly, we found that knockdown of IKKβ, but not NF-κB, dramatically impaired cell migration and invasion in these cells. Consistent with this, the IKKβ inhibitor, CmpdA, also inhibited cell migration and invasion. Previous studies have already shown that N-Cadherin, an epithelial-mesenchymal transition (EMT) marker, and IL-6, a pro-inflammatory cytokine, play important roles in regulation of HNSCC migration, invasion, and metastasis. We found that cisplatin-resistant HNSCC expressed higher levels of N-Cadherin and IL-6, which were significantly inhibited by CmpdA. More importantly, we showed that CmpdA treatment dramatically abated cisplatin-resistant HNSCC cell metastasis to lungs in a mouse model. Our data demonstrated the crucial role of IKKβ in control of migration, invasion, and metastasis, and implicated that targeting IKKβ may be a potential therapy for cisplatin-resistant metastatic HNSCC.

Entities:  

Keywords:  Cisplatin resistance; HNSCC; Head and neck squamous cell carcinoma; IKKβ; IKKβ inhibitor; Invasion; Metastasis; Migration; NF-κB

Mesh:

Substances:

Year:  2020        PMID: 32020377      PMCID: PMC7305835          DOI: 10.1007/s10585-020-10021-7

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  33 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 2.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

3.  MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.

Authors:  L Sun; Y Yao; B Liu; Z Lin; L Lin; M Yang; W Zhang; W Chen; C Pan; Q Liu; E Song; J Li
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

Review 4.  Epidermal growth factor receptor biology in head and neck cancer.

Authors:  Shailaja Kalyankrishna; Jennifer R Grandis
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

5.  Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1.

Authors:  Chia-Wei Li; Weiya Xia; Longfei Huo; Seung-Oe Lim; Yun Wu; Jennifer L Hsu; Chi-Hong Chao; Hirohito Yamaguchi; Neng-Kai Yang; Qingqing Ding; Yan Wang; Yun-Ju Lai; Adam M LaBaff; Ting-Jung Wu; Been-Ren Lin; Muh-Hwa Yang; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2012-01-17       Impact factor: 12.701

6.  A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.

Authors:  Karl Ziegelbauer; Florian Gantner; Nicholas W Lukacs; Aaron Berlin; Kinji Fuchikami; Toshiro Niki; Katsuya Sakai; Hisayo Inbe; Keisuke Takeshita; Mina Ishimori; Hiroshi Komura; Toshiki Murata; Timothy Lowinger; Kevin B Bacon
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 7.  Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature.

Authors:  Guilherme Rabinowits; Robert I Haddad
Journal:  Oral Oncol       Date:  2012-07-25       Impact factor: 5.337

Review 8.  The current state of head and neck cancer gene therapy.

Authors:  Sufi Mary Thomas; Jennifer Rubin Grandis
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

9.  Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.

Authors:  Yanting Zhang; Rena G Lapidus; Peiyan Liu; Eun Yong Choi; Samusi Adediran; Arif Hussain; Xinghuan Wang; Xuefeng Liu; Han C Dan
Journal:  Mol Cancer Ther       Date:  2016-04-08       Impact factor: 6.261

10.  IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus.

Authors:  Miao-Fen Chen; Ping-Tsung Chen; Ming Shian Lu; Paul Yang Lin; Wen-Cheng Chen; Kuan-Der Lee
Journal:  Mol Cancer       Date:  2013-04-05       Impact factor: 27.401

View more
  3 in total

1.  Emodin Reverses Gemcitabine Resistance of Pancreatic Cancer Cell Lines Through Inhibition of IKKβ/NF-κB Signaling Pathway.

Authors:  Hongfei Tong; Zhen Huang; Hui Chen; Bin Zhou; Yi Liao; Zhaohong Wang
Journal:  Onco Targets Ther       Date:  2020-10-02       Impact factor: 4.147

Review 2.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

3.  Paclitaxel resistance is mediated by NF-κB on mesenchymal primary breast cancer cells.

Authors:  José Esparza-López; Ossian Longoria; Eliseo Neftali De La Cruz-Escobar; Julio Cesar Garibay-Díaz; Eucario León-Rodríguez; María De Jesús Ibarra-Sánchez
Journal:  Oncol Lett       Date:  2021-12-16       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.